Back

Effectiveness, safety, and composite clinical outcomes of apixaban, dabigatran, rivaroxaban, relative to warfarin in non-valvular atrial fibrillation patients in the US Medicare population

27 August 2018 (08:30 - 12:30)
Organised by:
Congress Presentation Part of: Poster Session 4 - Atrial fibrillation - Stroke prevention Oral Anticoagulation ESC Premium Access ESC Congress 2018

About the speaker

Photo
Mr Amol Dhamane

Bristol-Myers Squibb, Lawrenceville (United States of America)

27 More presentations in this session

Presentation thumbnail
Professor P. Penson (Liverpool, GB)
Abstract Slides
Presentation thumbnail
Doctor I. Cavallari (Rome, IT)
Abstract Slides
Presentation thumbnail
Doctor A. Jhand (Omaha, US)
Abstract Slides
Presentation thumbnail
Doctor A. Thandra (Omaha, US)
Abstract Slides
Presentation thumbnail
Doctor S. Pokorney (Durham, US)

Access the full session

Session thumbnail
Poster Session 4 - Atrial fibrillation - Stroke prevention

The Event

Event poster

ESC Congress 2018

27 August 2018 08:30 CET
You may be interested in
thumbnail
Congress Presentation
Comparison of warfarin, dabigatran, rivaroxaban and apixaban for effectiveness and safety among elderly patients with atrial fibrillation: a nationwide cohort study
31 August 2020
thumbnail
Congress Session
Comorbidity management in patients presenting with atrial fibrillation – the EHRA-PATHS Project
7 April 2024
thumbnail
Congress Presentation
A new clinical decision support tool based on personalized evidence-based medicine improves outcomes of anticoagulation therapy in patients with atrial fibrillation: an analysis from the AF Registry
29 June 2021
thumbnail
Congress Presentation
Ophthalmic complications in patients with nonvalvular atrial fibrillation and type 2 diabetes prescribed rivaroxaban or warfarin
25 April 2021

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources